Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bi-Coastal Pharmaceutical has acquired the US marketing rights to Aquoral artificial saliva, a lipid-based artificial saliva spray product that is reported to be the only prescription spray product marketed in the US to treat xerostomia.
Subscribe to our email newsletter
The product is sold in a 40ml spray bottle that if used as directed is a two-month supply.
Ralph Massa, Jr, Bi-Coastal Pharmaceutical’s president and COO, said: “I am pleased to announce the acquisition of Aquoral and confident that we will achieve significant sales levels well within the first year of marketing the product.
“Aquoral will soon be a trusted and proven household name to treat xerostomia as it is an extremely effective and easy to use product with no known adverse effects.”